Neuralstem Announces Proposed Public Offering of Common Stock and Warrants
July 26 2017 - 4:50PM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced it has commenced an underwritten public offering, subject
to market and other conditions, to issue and sell shares of its
common stock and warrants to purchase shares of its common stock.
There can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Canaccord Genuity is acting as sole book-running manager for the
offering.
The shares of common stock and warrants to purchase shares of
common stock described above are being offered pursuant to a shelf
registration statement previously filed with and declared effective
by the Securities and Exchange Commission (SEC). A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available for free
on the SEC’s website at www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
the offering may also be obtained, when available, from Canaccord
Genuity Inc., Attention: Equity Syndicate Department, 99 High
Street, 12th Floor, Boston, Massachusetts 02110, by telephone at
(617) 371-3900, or by email at prospectus@canaccordgenuity.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of Neuralstem’s securities. No
offer, solicitation or sale will be made in any state or other
jurisdiction in which such offering, solicitation or sale would be
unlawful.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. NSI-189 is the lead compound in Neuralstem’s
neurogenic small molecule program. NSI-566 is a stem cell
therapy being tested in stroke, chronic spinal cord injury (cSCI)
and Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s
diversified portfolio of product candidates is based on its
proprietary neural stem cell technology.
Forward-Looking Statements
This press release contains "forward-looking statements" made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including statements regarding the
proposed public offering. The offering is subject to market and
other conditions and there can be no assurance as to whether or
when the offering may be completed or as to the actual size or
terms of the offering. These forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ
materially, including market conditions, risks associated with the
cash requirements of our business and other risks detailed from
time to time in our filings with the SEC, and represent our views
only as of the date they are made and should not be relied upon as
representing our views as of any subsequent date. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as "expect," "anticipate,"
"intend," "estimate," "plan," "believe," "seek," "may" or "will."
Forward-looking statements by their nature address matters that
are, to different degrees, uncertain. Specific risks and
uncertainties that could cause our actual results to differ
materially from those expressed in our forward-looking statements
include risks inherent in the development and commercialization of
potential products, uncertainty of clinical trial results or
regulatory approvals or clearances, need for future capital,
dependence upon collaborators and maintenance of our intellectual
property rights. Actual results may differ materially from the
results anticipated in these forward-looking statements. Additional
information on potential factors that could affect our results and
other risks and uncertainties are detailed from time to time in
Neuralstem's periodic reports, including the Annual Report on Form
10-K for the year ended December 31, 2016, and filed with the
Securities and Exchange Commission (SEC) on March 23, 2017, and in
other reports filed with the SEC. We do not assume any obligation
to update any forward-looking statements.
For further information, please contact:
Danielle Spangler
Director of Investor Relations, Neuralstem
dspangler@neuralstem.com
301-366-1481
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2023 to Apr 2024